Dr. David Tabatadze, President and CEO of ZATA will present ZATA’s new generation oligonucleotides at the “Discovery on Target” meeting in Boston, MA on September 25-29, 2017 (http://www.discoveryontarget.com/Oligonucleotide-Therapeutics).The meeting will address advances in genomics, gene editing, oligonucleotide synthesis, delivery and manufacturing.
Dr. Ivan Ianachkov, VP of Medicinal Chemistry, has presented for the first time ZATA’s Oligonucleotide technology to the professional community at the Gordon Scientific Conference in Newport, MA Nucleosides, Nucleotides and Oligonucleotides (https://www.grc.org/programs.aspx?id=12058). The scientific community received ZATA’s technology with high interest and enthusiasm.
ZATA relocated to MBI’s new Gateway Park facility in Worcester, MA. The facility is located within the WPI Life Sciences & Bioengineering Center (LSBC) at Gateway Park and possess unique set-ups for the ZATA’s lab operations. The location has excellent access to Downtown Worcester and to all of New England via I-290, I-190, and the MassPike.
R&D team of ZATA published the manuscript describing ZATA’s novel self-neutralizing oligonucleotides with enhance cellular uptake.
For more information about published compounds as well as viewing earlier patent application: WO/2016/081600 International application No.: PCT/US2015/061343
President of ZATA participated NIH sponsored Life Science Summit in New-York City where he presented ZATA blood sterilization closed systems and explored potential collaboration opportunities (http://lifesciencessummit.org/).
Dr. Ivan B. Yanachkov joined ZATA as VP of Medical Chemistry. Before that Dr. Yanachkov held the position of VP at GLSynthesis, Inc. (Worcester, MA). His extensive experience in the design, synthesis, and testing of large numbers of drug candidates significantly strengthens ZATA’s interdisciplinary team. ZATA welcomes Dr. Yanachkov on board.
Canadian Patent Application No.: 2930562 Based on International Application No.: PCT/US2014/065367 Entitled: “AZIRIDINYL CONTAINING COMPOUNDS AND METHODS OF INACTIVATING NUCLEIC ACID MOLECULES USING THE SAME” was filed by Pepper Hamilton LLP (Boston, MA) on behalf of ZATA.
U.S. National Phase Application No.: 15/036,675 with title: “Aziridinyl Containing Compounds And Methods Of Inactivating Nucleic Acid Molecules Using Same” was filed by Pepper Hamilton LLP (Boston, MA) on behalf of ZATA.
ZATA welcomes Dr. Boris Zavizion as its Director of biology.
Prior to joining ZATA, he held the position of Director of Biology at BioSense, Inc. (Auburn, MA). Dr Zavizion’s background and expertise in microbiology and molecular biology are a valuable addition to ZATA’s interdisciplinary team.
ZATA has been awarded by NIH SPIR Phase II – Application title: SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR”. Application ID: 5R44GM109517-03. PI – David Tabatadze, PhD.